Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

NEXT STORY
Signature Resources Provides a Project Update on Ongoing Drilling Activities at Its 100% Owned Lingman Lake Gold Project
PREV STORY
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Abiomed Surpasses 50,000 Impella® Patients Treated in the United States

DANVERS, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider ...

author_avatar
NASDAQ Market News

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is projected to reach US$56,737.2 Million in 2031: Visiongain Research Inc

author_avatar
NASDAQ Market News

electroCore Announces Fourth Quarter and Full Year 2019 Financial Results

author_avatar
NASDAQ Market News